StreetInsider.com News Articles

Form 8-K/A Ensysce Biosciences, For: Aug 05

Fri, 16 Oct 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20261016/27195260.html

Form 8-K Ensysce Biosciences, For: Sep 25

Tue, 29 Sep 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260929/27118069.html

Ensysce Biosciences submits Phase 2a protocol for CY200 to UK regulator

Thu, 24 Sep 2026 08:02:42 -0400

Ensysce Biosciences, Inc. (NASDAQ: ENSC) has submitted a Phase 2a clinical study protocol for its drug candidate CY200 to the UK Medicines and Healthcare products Regulatory Agency (MHRA), according to a company press release.

The submitted protocol, designated CYBIO_001, is titled "A Phase 2A, Multicenter, Randomised, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of CY200 in Participants with Complex Regional Pain Syndrome Type 1." The study is designed to evaluate CY200's analgesic efficacy compared to placebo in adult participants with CRPS Type 1.

CY200 is described by the company as a neuroplastogenic therapy and is the newest

Ensysce Biosciences Phase 2 Protocol for CY200 - A Neuroplastigen for the Treatment of CRPS - Submitted to the UK MHRA

Thu, 24 Sep 2026 08:00:00 -0400

SAN DIEGO, CA / ACCESS Newswire / September 24, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on CRPS (Complex Regional Pain Syndrome), today announced the submission of the protocol for a Phase 2a clinical study of CY200, the Company's newest drug candidate from the newly acquired Cy Biopharma Inc.

This landmark milestone involved the submission of protocol CYBIO_001 entitled "A Phase 2A, Multicenter, Randomised, Double-blind, Placebo-controlled, Parallel-group, Proof of-Concept Study to Evaluate the

Ensysce Biosciences Phase 2 Protocol for CY200 - A Neuroplastigen for the Treatment of CRPS - Submitted to the UK MHRA

Thu, 24 Sep 2026 08:00:00 -0400

SAN DIEGO, CA / ACCESS Newswire / September 24, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on CRPS (Complex Regional Pain Syndrome), today announced the submission of the protocol for a Phase 2a clinical study of CY200, the Company's newest drug candidate from the newly acquired Cy Biopharma Inc.
This landmark milestone involved the submission of protocol CYBIO_001 entitled "A Phase 2A, Multicenter, Randomised, Double-blind, Placebo-controlled, Parallel-group, Proof of-Concept Study to Evaluate the

Ensysce Biosciences presents at PainWeek, joins FDA psychedelics hearing

Tue, 15 Sep 2026 09:16:30 -0400

Ensysce Biosciences, Inc. (NASDAQ: ENSC), a clinical-stage biotechnology company, hosted a symposium at PainWeek 2026 attended by more than 320 pain management professionals, according to a company press release.
Dr. Jeff Gudin presented on the company's program to develop opioids for severe pain and provided background on Complex Regional Pain Syndrome Type 1 (CRPS). Dr. Richard Langford outlined Ensysce's approach to CRPS, including a platform added through the company's acquisition of Cy Biopharma.
Following PainWeek, a team from Ensysce attended an FDA hearing on psychedelic drug regulation. The hearing covered regulatory frameworks, professional training and credentialing, patient safety, and real-world data collection

Ensysce Biosciences presents at PainWeek, joins FDA psychedelics hearing

Tue, 15 Sep 2026 09:16:30 -0400

Ensysce Biosciences, Inc. (NASDAQ: ENSC), a clinical-stage biotechnology company, hosted a symposium at PainWeek 2026 attended by more than 320 pain management professionals, according to a company press release.
Dr. Jeff Gudin presented on the company's program to develop opioids for severe pain and provided background on Complex Regional Pain Syndrome Type 1 (CRPS). Dr. Richard Langford outlined Ensysce's approach to CRPS, including a platform added through the company's acquisition of Cy Biopharma.
Following PainWeek, a team from Ensysce attended an FDA hearing on psychedelic drug regulation. The hearing covered regulatory frameworks, professional training and credentialing, patient safety, and real-world data collection

Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation

Tue, 15 Sep 2026 09:15:00 -0400

SAN DIEGO, CA / ACCESS Newswire / September 15, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company") a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on CRPS (Complex Regional Pain Syndrome), hosted a symposium at PainWeek 2026. The Symposium was attended by more than 320 pain management professionals. Dr. Jeff Gudin provided background on the Ensysce novel program to provide safer opioids for severe pain as well as a substantial background on complex pain, specifically Complex Regional Pain Syndrome Type 1 (CRPS). Dr.

Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation

Tue, 15 Sep 2026 09:15:00 -0400

SAN DIEGO, CA / ACCESS Newswire / September 15, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company") a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on CRPS (Complex Regional Pain Syndrome), hosted a symposium at PainWeek 2026. The Symposium was attended by more than 320 pain management professionals. Dr. Jeff Gudin provided background on the Ensysce novel program to provide safer opioids for severe pain as well as a substantial background on complex pain, specifically Complex Regional Pain Syndrome Type 1 (CRPS). Dr.

Ensysce Biosciences' Professor Richard Langford Selected to Speak at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs

Mon, 14 Sep 2026 08:00:00 -0400

SAN DIEGO, CA / ACCESS Newswire / September 14, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company") a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on CRPS (Complex Regional Pain Syndrome), today announced that Richard Langford, Chief Medical Officer of Cy Biopharma, has been selected to present in person at the U.S. Food and Drug Administration's ("FDA") public hearing, "Considerations for Potential Future Therapeutic Use of Psychedelic Drugs," being held today, Monday, September 14, 2026 at the FDA's White Oak Campus in Silver

Ensysce Biosciences' Professor Richard Langford Selected to Speak at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs

Mon, 14 Sep 2026 08:00:00 -0400

SAN DIEGO, CA / ACCESS Newswire / September 14, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company") a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on CRPS (Complex Regional Pain Syndrome), today announced that Richard Langford, Chief Medical Officer of Cy Biopharma, has been selected to present in person at the U.S. Food and Drug Administration's ("FDA") public hearing, "Considerations for Potential Future Therapeutic Use of Psychedelic Drugs," being held today, Monday, September 14, 2026 at the FDA's White Oak Campus in Silver

Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation

Wed, 02 Sep 2026 08:30:00 -0400

SAN DIEGO, CA / ACCESS Newswire / September 2, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company") a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on CRPS (Complex Regional Pain Syndrome), today announced its participation in the following upcoming investors conferences and industry events.
2026 Cantor Global Healthcare Conference being held Wednesday, September 9^th to Saturday, September 12^th at the Waldorf Astoria in New York City. The Company will host a presentation at 9:10am ET on Friday, September 10^th.
The H.C. Wainwright 28^th Annual

Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation

Wed, 02 Sep 2026 08:30:00 -0400

SAN DIEGO, CA / ACCESS Newswire / September 2, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company") a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on CRPS (Complex Regional Pain Syndrome), today announced its participation in the following upcoming investors conferences and industry events.
2026 Cantor Global Healthcare Conference being held Wednesday, September 9^th to Saturday, September 12^th at the Waldorf Astoria in New York City. The Company will host a presentation at 9:10am ET on Friday, September 10^th.
The H.C. Wainwright 28^th Annual

Ensysce completes enrollment in final stage of opioid study

Mon, 31 Aug 2026 08:32:03 -0400

Ensysce Biosciences, Inc. (NASDAQ: ENSC) announced the completion of enrollment in Part 3 of its PF614-MPAR-102 clinical study, the second study evaluating its MPAR® (Multi-Pill Abuse Resistance) overdose-protection technology.
The study, supported by the National Institute on Drug Abuse (NIDA) under Award Number DA047682, was designed to characterize the drug's protective profile across a range of dosing scenarios. According to the company, clinical data published to date shows PF614-MPAR maintains consistent therapeutic plasma levels at normal doses while limiting exposure increases at supratherapeutic levels.
PF614-MPAR holds Breakthrough Therapy designation. The drug uses a chemical-control mechanism intended to provide therapeutic opioid exposure at

Ensysce completes enrollment in final stage of opioid study

Mon, 31 Aug 2026 08:32:03 -0400

Ensysce Biosciences, Inc. (NASDAQ: ENSC) announced the completion of enrollment in Part 3 of its PF614-MPAR-102 clinical study, the second study evaluating its MPAR® (Multi-Pill Abuse Resistance) overdose-protection technology.
The study, supported by the National Institute on Drug Abuse (NIDA) under Award Number DA047682, was designed to characterize the drug's protective profile across a range of dosing scenarios. According to the company, clinical data published to date shows PF614-MPAR maintains consistent therapeutic plasma levels at normal doses while limiting exposure increases at supratherapeutic levels.
PF614-MPAR holds Breakthrough Therapy designation. The drug uses a chemical-control mechanism intended to provide therapeutic opioid exposure at

Ensysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical Study

Mon, 31 Aug 2026 08:30:00 -0400

~ ~ The Second Study Fully Enrolled for Breakthrough Therapy-Designated, First-in-Class Opioid Designed to Protect Against Oral Overdose ~ ~

SAN DIEGO, CA / ACCESS Newswire / August 31, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on complex pain, and advancing next-generation pain and central nervous system therapeutics designed to reduce abuse and overdose risk, today announced completion of enrollment in the final stage of the PF614-MPAR-102 clinical study. The study evaluated its

Ensysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical Study

Mon, 31 Aug 2026 08:30:00 -0400

~ ~ The Second Study Fully Enrolled for Breakthrough Therapy-Designated, First-in-Class Opioid Designed to Protect Against Oral Overdose ~ ~

SAN DIEGO, CA / ACCESS Newswire / August 31, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on complex pain, and advancing next-generation pain and central nervous system therapeutics designed to reduce abuse and overdose risk, today announced completion of enrollment in the final stage of the PF614-MPAR-102 clinical study. The study evaluated its

Form 8-K Ensysce Biosciences, For: Aug 25

Tue, 25 Aug 2026 17:12:00 -0400
si-local-file:///var/storage/secattach/20260825/26975671.html

Form 8-K Ensysce Biosciences, For: Aug 25

Tue, 25 Aug 2026 17:12:00 -0400
si-local-file:///var/storage/secattach/20260825/26975671.html

Form 8-K Ensysce Biosciences, For: Aug 24

Mon, 24 Aug 2026 17:13:00 -0400
si-local-file:///var/storage/secattach/20260824/26969100.html

Form 8-K Ensysce Biosciences, For: Aug 24

Mon, 24 Aug 2026 17:13:00 -0400
si-local-file:///var/storage/secattach/20260824/26969100.html

Form D Ensysce Biosciences,

Thu, 20 Aug 2026 14:14:00 -0400
si-local-file:///var/storage/secattach/20260820/26955560.html

Form D Ensysce Biosciences,

Thu, 20 Aug 2026 14:14:00 -0400
si-local-file:///var/storage/secattach/20260820/26955560.html

Ensysce Biosciences to Showcase "A New Era in Pain Therapeutics" at PAINWeek 2026 Symposium

Thu, 20 Aug 2026 08:00:00 -0400

~Major symposium to highlight breakthrough innovations in severe pain and Complex Regional Pain Syndrome (CRPS) ~
~Discussions to feature a first-in-class approach to neural reset and novel chemical safety switch technology ~

SAN DIEGO, CA / ACCESS Newswire / August 20, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company") a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on complex pain, today announced that it will host an educational symposium at PAINWeek 2026, entitled A New Era in Pain Therapeutics.
The symposium will present

Ensysce Biosciences to Showcase "A New Era in Pain Therapeutics" at PAINWeek 2026 Symposium

Thu, 20 Aug 2026 08:00:00 -0400

~Major symposium to highlight breakthrough innovations in severe pain and Complex Regional Pain Syndrome (CRPS) ~
~Discussions to feature a first-in-class approach to neural reset and novel chemical safety switch technology ~

SAN DIEGO, CA / ACCESS Newswire / August 20, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company") a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on complex pain, today announced that it will host an educational symposium at PAINWeek 2026, entitled A New Era in Pain Therapeutics.
The symposium will present